Movement Alert|Aehr Test Rises 8.18% in Regular Trading, Oppenheimer Initiates Coverage With Outperform Rating and $120 Target

Market Focus00:19

On September 17, Aehr Test rose 8.18% in regular trading, trading at $90.68 USD/share, with turnover of $127 million, rebounding sharply from recent lows hit during a broader semiconductor sector pullback.

The rally was driven by Oppenheimer initiating coverage on the company with an Outperform rating and a $120 price target. The firm highlighted that Aehr Test is positioned for an AI-driven inflection, as rising chip power and package value increases the cost of late-stage failures, making burn-in testing increasingly critical. Oppenheimer projected fiscal Q2 2027 revenue of $43.7 million, well above the $37 million consensus, and H1 revenue of $70.9 million versus the Street estimate of $63 million, citing strong Sonoma backlog.

Fundamental momentum further supported the move. The company secured a record $41 million order for its package-level burn-in platform Sonoma from a leading hyperscaler, while its wafer-level FOX-XP platform entered high-volume manufacturing with a major AI processor customer, including a $22 million follow-on order for systems to be shipped to Taiwan over six months. AI data center-related revenue is expected to account for approximately 70% of fiscal 2027 sales.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment